Showing results (31-40 of 147) with videos related to
Sort By:
Pageof 15
Transplantation|March 1, 1986
In vivo mechanisms of alloreactivity. III. Development of donor-specific antibody in sponge matrix allograftsL P Sirinek, N E Zinn, R M Ferguson, et al.Transplantation|July 31, 1999
Medication compliance following renal transplantationL R Raiz, K M Kilty, M L Henry, et al.Pediatric Nephrology (Berlin, Germany)|January 1, 1995
A clinical trial of cyclosporine G in cadaveric renal transplantationM L Henry, E A Elkhammas, E A Davies, et al.Transplantation|April 1, 1993
A randomized, prospective, double-blinded trial of cyclosporine vs. OG37-325 in cadaveric renal transplantation--a preliminary reportM L Henry, R J Tesi, E A Elkhammas, et al.Transplantation|May 1, 1993
OKT3 for primary therapy of the first rejection episode in kidney transplantsR J Tesi, E A Elkhammas, M L Henry, et al.Clinical Transplants|January 1, 1992
Combined kidney/pancreas transplantation at the Ohio State University HospitalsE A Elkhammas, M L Henry, R J Tesi, et al.The Journal of Surgical Research|May 1, 1983
The role of heparin in guinea pig gram negative bacterial sepsisD L Dunn, P A Mach, F B Cerra, et al.Transplantation Proceedings|February 1, 1987
Primary cadaveric renal transplantation using cyclosporine in patients over fifty years of ageD M Mandelbaum, M L Henry, B G Sommer, et al.International Journal of Immunopharmacology|January 1, 1988
In vivo mechanisms of alloreactivity--IV. Cyclosporine differentially impairs accumulation of donor-reactive CTL but not donor-reactive alloantibody in murine sponge matrix allograftsC G Orosz, N E Zinn, L P Sirinek, et al.Surgery|February 1, 1988
Histamine type-2 receptor antagonist immune modulation. I. Increased cell-mediated cytotoxicity in normal and in down-regulated systemsR R Gifford, B V Voss, J R Schmidtke, et al.Pageof 15